Unknown PHASE2 INTERVENTIONAL 5-arm NCT03741426

WIRE - Novel Treatments in Renal Cell Cancer (WIRE)

WIndow of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in REnal Cell Cancer

Sponsor: AstraZeneca

Interventions Cediranib Durvalumab Olaparib

Updated 8 times since 2018 Last updated: Jun 5, 2023 Started: Jul 27, 2020 Primary completion: Nov 30, 2025 Completion: Nov 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Renal Cell Cancer and is currently ongoing. AstraZeneca leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Unknown Status → Recruiting
Jun 2023 — Jul 2023 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2021 — Jun 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Jun 2021 [monthly]

Not Yet Recruiting PHASE2
Dec 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
CCTU- Cancer Theme
Cancer Research UK
University of Cambridge

Data source: Cambridge University Hospitals NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United Kingdom
• Glasgow, United Kingdom